Malaria is a treatable communicable disease yet remains a common cause of death and disease especially among pregnant women and children. Most of malaria's worldwide burden disproportionately lies in Southeast Asia and Sub-Saharan Africa. Western medicine's 100+ year history of combating Plasmodium falciparum has taught us that the global population of malaria parasites has a unique and dangerous ability to rapidly evolve and spread drug resistance. Recently it was documented that resistance to the first-line antimalarial artemisinin may be developing in Southeast Asia.
The goal of this work is to develop new targets for antimalarial drug development and use these new tools to better understand the evolutionary process of adaptation to antimalarial drugs. We focused on derivatives of the natural product antimalarial febrifugine. We first identified that febrifugine derivative halofuginone targets the P. falciparum cytoplasmic prolyl tRNA synthetase (cPRS). We then found another febrifugine derivative, halofuginol, which shared halofuginone's mechanism of action but lacked its toxicity in an in vivo murine model of malaria.
By studying the multiple mechanisms that P. falciparum utilizes to evolve resistance to halofuginone, we present a three-step sequential model of the evolution of drug resistance in malaria. In the case of halofuginone, we found non-genetic regulation of the clag family of genes achieved specific increase of proline pools in addition to genetic modification of the cPRS were fundamental in the evolution of resistance.
By focusing on cPRS drug resistance mutations with a reverse genetic approach, we further found evidence that drug resistance mutations can be the second of a two-step evolutionary process. We found that both cPRS mutations L482F (HFGRI) and L482H (HFGRII) required a cellular environment with the overexpression of clag gene family members to confer resistance to halofuginone.
Taken together, these data identify the cPRS as a new and promising target for malaria drug development, halofuginol as a promising chemical scaffold for the development of future cPRS-based antimalarials, and a new model of the evolution of drug resistance involving sequential non-genetic and genetic adaptations.
|Advisor:||Wirth, Dyann F.|
|Commitee:||Duraisingh, Manoj, Garraway, Levi, Gray, Nathanael, Winzeler, Elizabeth|
|Department:||Biology: Medical Sciences, Division of|
|School Location:||United States -- Massachusetts|
|Source:||DAI-B 75/10(E), Dissertation Abstracts International|
|Subjects:||Evolution and Development, Alternative Medicine, Public health, Parasitology|
|Keywords:||Drug resistance, Evolution, Halofuginone, Malaria, Non-genetic adaptation, tRNA synthetase|
Copyright in each Dissertation and Thesis is retained by the author. All Rights Reserved
The supplemental file or files you are about to download were provided to ProQuest by the author as part of a
dissertation or thesis. The supplemental files are provided "AS IS" without warranty. ProQuest is not responsible for the
content, format or impact on the supplemental file(s) on our system. in some cases, the file type may be unknown or
may be a .exe file. We recommend caution as you open such files.
Copyright of the original materials contained in the supplemental file is retained by the author and your access to the
supplemental files is subject to the ProQuest Terms and Conditions of use.
Depending on the size of the file(s) you are downloading, the system may take some time to download them. Please be